Brief: Sol-Gel And Mayne Pharma Announce The Purchase Of Epsolay And Twyneo In The U.S.
April 17 (Reuters) - Mayne Pharma Group Ltd MYX.AX: SOL-GEL AND MAYNE PHARMA ANNOUNCE THE PURCHASE OF EPSOLAY® AND TWYNEO® IN THE U.S. SOL-GEL- TO RECEIVE $16 MILLION DURING 2025 SOL-GEL- SGT-610 PHASE III TRIAL TOP-LINE RESULTS EXPECTED Q4 2026 Source text: ID:nGNX9BXqdP Further company coverage: MYX.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mayne Pharma
See all newsBrief: Mayne Pharma Group Says It Settles Us Patent Litigation Re Imvexxy With Teva USA
Deals of the day-Mergers and acquisitions
Brief: Mayne Pharma Says Supreme Court Dismisses Cosette Appeal
Deals of the day-Mergers and acquisitions
Australian court dismisses Cosette appeal to drop Mayne Pharma takeover (updated)